Aegon N.V. 8.00% (AEK) 27.10 $AEK Azarga Provides Update

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aegon N.V. 8.00% (AEK) 27.10 $AEK

Azarga Provides Update on Investee Companies
Marketwire Canada - Tue Sep 08, 3:05PM CDT
AZARGA URANIUM CORP. (TSX:AZZ)(OTC PINKWURF)(FRANKFURT8AA) ("Azarga" or the "Company" notes that the previously announced transactions involving its investee companies, Black Range Minerals Limited ("Black Range" and Anatolia Energy Limited ("Anatolia Energy" continue to advance.
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

Chairman Takes Temporary Leave of Absence and Blake Steele Assumes President Role
Marketwire Canada - Mon Aug 10, 7:46AM CDT
AZARGA URANIUM CORP. (TSX:AZZ)(OTC PINKWURF)(FRANKFURT8AA) ("Azarga" or the "Company" announces that its Chairman and CEO, Alexander Molyneux, has informed the Company that he will be taking a temporary leave of absence.
PDN.TO: 0.19 (unch), AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03), PDN: 26.64 (-0.25)

Cantor Fitzgerald Initiates Research Coverage on Azarga
Marketwire Canada - Thu Jul 23, 8:00AM CDT
AZARGA URANIUM CORP. (TSX:AZZ)(OTC PINKWURF)(FRANKFURT8AA) ("Azarga" or the "Company" announces that Cantor Fitzgerald Inc. ("Cantor Fitzgerald" has initiated equity research coverage on Azarga.
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

Azarga Uranium Corp.: Election of Directors Voting Results and Adoption of Majority Voting Policy
Marketwired - Tue Jul 14, 7:31AM CDT
AZARGA URANIUM CORP. (TSX: AZZ)(OTC PINK: PWURF)(FRANKFURT: P8AA) ("Azarga" or the "Company" announces that the nominees listed in the management proxy circular dated 19 May 2015 for the Annual General and Special Meeting (the "Meeting" of the Company held on 30 June 2015 were all elected as directors of the Company. Detailed results of the vote for the election of directors held at the Meeting are set out below:
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

Azarga Uranium Corp.: Annual General and Special Meeting 2015 Voting Results
Marketwired - Wed Jul 08, 7:31AM CDT
AZARGA URANIUM CORP. (TSX: AZZ)(OTC PINK: PWURF)(FRANKFURT: P8AA) ("Azarga" or the "Company" announces all resolutions put forward at the Annual General and Special Meeting (the "Meeting", as further described in the Company's information circular dated 19 May 2015, were approved, including the following:
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

ASLB Decision Review Process Makes Progress
Marketwired - Fri Jun 26, 7:38AM CDT
AZARGA URANIUM CORP. (TSX: AZZ)(FRANKFURT: P8AA)(OTC PINK: PWURF) ("Azarga" or the "Company" notes that progress continues with respect to the review of various contentions decided in the 30 April 2015 decision of the United States Atomic Safety and Licensing Board ("ASLB" pertaining to the NRC Final Source and Byproduct Materials License ("NRC Final License" for the Dewey Burdock Uranium Project (as announced by the Company on 27 May 2015).
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

Uranium Resources and Anatolia Energy Announce Merger with Aim to Fast-Track Uranium Production
BusinessWire - Wed Jun 03, 8:25AM CDT
Uranium Resources Inc. (Uranium Resources or URI) (NASDAQ:URRE) and Anatolia Energy Limited (Anatolia) (ASX:AEK) are pleased to announce that they have reached an agreement to combine the two companies to create a larger, diversified uranium development and exploration business, with the aim of becoming a low-cost uranium producer in the near term from the Temrezli Project in central Turkey.
URRE: 1.31 (-0.01), AEK: 27.10 (+0.03)

Azarga and NRC File for Appeal of ASLB Decision
Marketwired - Wed May 27, 4:19PM CDT
AZARGA URANIUM CORP.'S (TSX: AZZ)(OTC PINK: PWURF)(FRANKFURT: P8AA) ("Azarga" or the "Company" wholly owned subsidiary, Powertech (USA) Inc. ("Powertech", and the United States Nuclear Regulatory Commission ("NRC" have both filed petitions for review of the 30 April 2015 decision of the United States Atomic Safety and Licensing Board ("ASLB" who ruled on seven contentions raised by the Consolidated Intervenors and the Oglala Sioux Tribe (collectively, the "Intervenors" regarding the NRC Final Source and Byproduct Materials License ("NRC Final License" for the Dewey Burdock Uranium Project.
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

NRC Final License Remains Effective With No Stay Filed by Intervenors
Marketwired - Thu May 14, 7:31AM CDT
AZARGA URANIUM CORP. (TSX: AZZ)(FRANKFURT: P8AA)(OTC PINK: PWURF) ("Azarga" or the "Company" and its wholly owned subsidiary Powertech (USA) Inc. ("Powertech" is pleased to announce that no stay has been filed against its United States Nuclear Regulatory Commission ("NRC" Final Source and Byproduct Materials License ("NRC Final License" for the Dewey Burdock Uranium Project within the period prescribed by the United States Atomic Safety and Licensing Board ("ASLB" in its decision of 30 April 2015.
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

US Atomic Safety and Licensing Board Partially Dismisses Contentions Against Dewey Burdock Uranium Project
Marketwired - Fri May 01, 7:31AM CDT
AZARGA URANIUM CORP. (TSX: AZZ)(FRANKFURT: P8AA)(OTC PINK: PWURF) ("Azarga" or the "Company" and its wholly owned subsidiary Powertech (USA) Inc. ("Powertech" is pleased to announce that the United States Atomic Safety and Licensing Board ("ASLB" ruled on seven contentions raised by the Consolidated Intervenors and the Oglala Sioux Tribe (collectively the "Intervenors" regarding the United States Nuclear Regulatory Commission ("NRC" Final Source and Byproduct Materials License ("NRC Final License" for the Dewey Burdock Uranium Project.
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

Azarga Updates Preliminary Economic Assessment for Dewey Burdock
Marketwired - Mon Apr 27, 7:53AM CDT
AZARGA URANIUM CORP. (TSX: AZZ)(FRANKFURT: P8AA)(OTC PINK: PWURD) ("Azarga" or the "Company" has filed an updated version of the preliminary economic assessment ("April PEA Update" entitled "Preliminary Economic Assessment, Dewey-Burdock Uranium ISR Project, South Dakota, USA" by Douglas H Graves, P.E. and Steve Cutler, P.G. dated effective 29 January 2015 and amended 21 April 2015. The April PEA Update replaces and supersedes the preliminary economic assessment previously filed on SEDAR on 14 March 2015 ("March PEA". The April PEA Update is prepared to meet the requirements of National Instrument 43-101 ("NI 43-101" and Form NI 43-101 F1 and comments provided by the British Columbia Securities Commission ("BCSC" related to a BCSC review of the March PEA. There were no changes to the resource estimate, production quantities, or before-income tax cost estimates.
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

ASLB Declares Evidentiary Portion of Hearing for Dewey Burdock License Closed
Marketwired - Fri Dec 12, 7:12AM CST
Azarga Uranium Corp. (TSX: AZZ)(OTC PINK: PWURD)(FRANKFURT: P8AA) -
AZZ.TO: 0.28 (-0.01), AEK: 27.10 (+0.03)

Powertech Uranium Corp.: Merger with Azarga Resources and $5.0m Financing Complete; Name change to Azarga Uranium Corp. and Share Consolidation Complete
Marketwired - Wed Oct 29, 7:07AM CDT
Powertech Uranium Corp. (now Azarga Uranium Corp.) (TSX: PWE) ("Azarga Uranium", "Powertech" or the "Company" has completed the merger with Azarga Resources Limited ("Azarga Resources" in accordance with the terms and conditions of the Share Purchase Agreement dated 25 February 2014, as amended, between the Company and Azarga Resources (the "Transaction" and the private placement financing for gross proceeds of approximately $5.0 million (the "Financing". In connection with the closing of the Transaction and the Financing, the Company has changed its name from "Powertech Uranium Corp." to "Azarga Uranium Corp." (the "Name Change" and completed a consolidation of its outstanding common shares on the basis of one (1) post-consolidation share for ten (10) pre-consolidation shares (the "Consolidation".
AEK: 27.10 (+0.03), PWE.TO: ()

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading